Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Sheraton Philadelphia Downtown Hotel

Oct 24, 2024 7:30 AM - Oct 25, 2024 4:10 PM

201 North 17th Street, Philadelphia, PA 19103

Real-World Evidence Conference

Translating Insights into Real-World Value

Session 1: A Year in Review

Session Chair(s)

SARAH K Martin, PhD, MS

SARAH K Martin, PhD, MS

Senior Director - Global Regulatory Policy (Oncology)

Eli Lilly & Co., United States

The session will explore new key milestones and major events in Real-World Evidence (RWE) since last year. The first presentation will provide a broad global overview of remarkable advances in RWE. The second presentation will summarize FDA’s RWD/E guidances on drugs and biologics products and highlight the draft non-interventional study guidance, provide an update on RWE commitments for PDUFA VII, and offer insights on how FDA centers are leveraging RWE. The third presentation will discuss applications of RWE in FDA Sentinel, including the scope and progress of projects in the RWE Data Enterprise and Sentinel’s PDUFA VII demonstration projects. The session will conclude with a panel discussion and audience Q&A.

Learning Objective :
  • Discuss draft and final guidances on RWE from US FDA including draft guidance on non-interventional studies
  • Describe FDA’s Sentinel demonstration projects
  • Recognize notable advances in RWE over the past year

Speaker(s)

Gabriel I Innes, DVM, PhD

Speaker

Gabriel I Innes, DVM, PhD

FDA, United States

Health Science Policy Analyst, OMP, CDER

Sarah  Dutcher, PhD, MS

Sarah Dutcher, PhD, MS

FDA, United States

Lead Epidemiologist, OSE, CDER

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.